×

Faber: Royalty Pharma Increases Bid for Elan

9:44 AM ET Fri, 7 June 2013

CNBC's David Faber reports the latest details on Royalty Pharma's offer to acquire Elan for $13 per share, plus continent value right based on future sales of Tysabri.